Home › Trials › NCT07270237

Multiparametric ultrasound imaging for pancreatic risk screening and thyroid nodules

Development and Evaluation of Ultrasound Imaging Acquisition and Analysis Methods

Not applicable Interventional Memorial Sloan Kettering Cancer Center · NCT07270237

This project will try multiparametric ultrasound (mpUS) to see if it gives clearer pictures of pancreatic tissue for people at high risk for pancreatic cancer and of thyroid nodules for people being evaluated for those lumps.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment85 (estimated)
Ages18 Years and up
SexAll
SponsorMemorial Sloan Kettering Cancer Center Academic / other
Locations7 sites (Basking Ridge, New Jersey and 6 other locations)
Trial IDNCT07270237 on ClinicalTrials.gov

What this trial studies

This interventional imaging protocol uses multiparametric ultrasound (mpUS) — combining multiple ultrasound techniques that show structure, blood flow, and microarchitecture — and compares its findings to standard ultrasound and other routine tests. One cohort focuses on people at high hereditary risk for pancreatic cancer who are undergoing endoscopic ultrasound; another cohort includes patients with thyroid nodules. Images from mpUS will be collected and compared to conventional imaging and diagnostic results to determine whether mpUS provides additional or more accurate information. The study is conducted through Memorial Sloan Kettering Cancer Center with consent sites listed in New Jersey.

Who should consider this trial

Good fit: Ideal candidates are people enrolled in MSK’s pancreatic registry who are undergoing endoscopic ultrasound because they are at high risk for pancreatic cancer, and patients being evaluated for thyroid nodules who are having ultrasound-based workup.

Not a fit: People who do not meet the MSK pancreatic registry criteria, are pregnant, or cannot undergo endoscopic ultrasound or the required imaging procedures are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, mpUS could provide clearer, more detailed imaging that helps doctors better distinguish cancerous from non-cancerous tissue and reduce unnecessary biopsies or delays in care.

How similar studies have performed: Early research and pilot studies of multiparametric ultrasound have shown promising improvements in lesion characterization, but mpUS remains an emerging technique that is not yet standard practice.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Cohort 1 - Feasibility of multiparametric endoscopic ultrasound (mpEUS) imaging of patients at high-risk for pancreatic cancer:

Patient Group: those having standard endoscopic ultrasounds because they are at high risk of pancreatic cancer Participants enrolled into the Memorial Sloan Kettering Cancer Center Pancreatic Registry protocol (IRB#: 02-102) will be eligible for this study. Specifically, related individuals without pancreatic cancer who are at-risk for developing pancreatic cancer and meet all of the following criteria (family health history will be self-reported):

* 10 years younger than the earliest pancreatic cancer diagnosis in the family
* Be at least 50 years old
* Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A/p16) or Hereditary Pancreatitis (PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)
* Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)
* Not pregnant and not Nursing
* Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)
* Must agree to be contacted for follow-up
* Must satisfy at least one of the following 4 criteria:

  1. Have at least two affected relatives who are a first-degree relative to each other, of whom at least one is a first degree relative to the individual OR have at least two affected first-degree relatives on the same side of the family.
  2. Have at least one first- or second-degree affected relative and have germline genetic test results that confirm a likely pathogenic or pathogenic variant in at least one of the following genes:

     1. APC (Familial Adenomatous Polyposis (FAP) and Attenuated FAP syndrome
     2. BRCA1(Hereditary Breast and Ovarian Cancer Symptoms)
     3. MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch Syndrome)
     4. PALB2
     5. TP53 (Li-Fraumeni Syndrome)
     6. Other established pancreatic cancer predisposition gene per project leader's discretion
  3. Have germline genetic test results that confirm a likely pathogenic or pathogenic variant in one or more of the following genes:

     1. CDKN2A/p16 (Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM))
     2. STK11 aka LKB1 (Peutz-Jeghers Syndrome)
     3. PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes per project leader's discretion
     4. ATM (ataxia telangiectasia mutated)
     5. BRCA 2(Hereditary Breast and Ovarian Cancer Symptoms)
  4. Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined the project leader (Dr. Vineet Rolston)

Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:

Patient Group: those with pancreatic cancer having endoscopic ultrasound-guided biopsies

Patients will be entered into the study if they meet the following criteria:

* Patients with pancreatic ductal adenocarcinoma
* Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care
* Not pregnant and not nursing

Cohort 3 - Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging:

Patient Group: those with a thyroid nodule that will be biopsied whether they have known cancer or not

* Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care
* Not pregnant and not nursing

Healthy Volunteers will be entered into the study if they meet the following criteria:

* No known cancer diagnosis or thyroid nodules
* Age ≥ 18
* Able to understand and give informed consent
* Not pregnant and not nursing

Exclusion Criteria:

Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:

* Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
* Under 18 years of age

Cohort 3 -Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging

* Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
* Under 18 years of age

Where this trial is running

Basking Ridge, New Jersey and 6 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Pancreatic CancerThyroid NoduleUltrasoundmpUS25-299
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.